http://multicorpinternational.com MultiCorp International, Inc. Announces the Hiring of Healthcare Executive to Become New Chief Executive Officer
45 minutes ago - DJNF
, Inc. Announces the Hiring of Healthcare Executive to Become New Chief Executive Officer
Mr. David Gustafson to Take Over as CEO of Company
SUN VALLEY, CA--(Marketwired - Feb 11, 2016) - , Inc, (OTC PINK: MCIC) announced today that the company has hired David Gustafson as the new CEO of the company.
The company released the following statement, ", Inc. is excited to announce that Mr. David Gustafson has taken over the helm of Chief Executive Officer of the company on an interim basis. The current CEO, Mr. Paul D. Lisenby, is taking a leave of absence due to medical reasons. There is no timetable for his return. In the meantime, we welcome Mr. Gustafson aboard as our CEO to spearhead the efforts of the company in the further development of the patented migraine medicine. Mr. Gustafson's 35 years of broad based, comprehensive, professional experience in the health care industry ranging from the operation of hospitals to medical groups, to integrated health delivery systems will benefit the company in developing and managing the 4-Arm Study the FDA is requiring for the migraine medicine, move the drug into further clinical trials, and to look for additional opportunities in the healthcare field for the company that can be capitalized upon to bring in additional revenue and profits. The Board of Directors also stated that they may possibly change the name of the company to further reflect the company's direction in the healthcare sector. The BOD also stated there will be no changes to the share structure of the company at this time."
About , Inc.
, Inc is committed itself to the further development of the patented migraine medicine the company owns a significant percentage of. The company has received information from the U.S. Food and Drug Administration that provides the company with a clear path to further the development of the drug to bring to market. The company is currently looking to partner with a pharmaceutical company that can assist the company in bringing the migraine medicine to market. For further information please contact them at [email protected]
About Mr. David Gustafson
David Gustafson is an executive with over 35 years of broad based, comprehensive, professional experience in the health care industry ranging from the operation of hospitals to medical groups, to integrated health delivery systems. Hospitals he managed have ranged in size from 49 to over 300 beds. His managed care experience ranges from design and implementation of a new managed care psychiatric treatment product for a major health plan, to launch of hospital based IPAs and a specialty IPA, to providing executive leadership for a hospital operating in a very tightly structured integrated healthcare delivery system, successful start-up of an ACO, and more recently, managing two IPAs serving over 42,000 members in the Inland Empire of Southern California.
In playing out the Senior Executive's external role he has served in a variety of community organizations such as the United Way, Chamber of Commerce, and service clubs. A frequent public speaker he has served on the adjunct faculty of Concordia College, Moorhead Minnesota, and has lectured at Pepperdine University, before a variety of clubs and organizations, and at hospital association seminars.
David holds a B.A. Degree in Business from Moorhead State University in Minnesota, and a Master's Degree in Hospital Administration from the University of Minnesota, a program for which he has served as a preceptor and mentor.
David Gustafson President at Gustafson + Associates, LLC Greater Los Angeles AreaHospital & Health Care Current Gustafson + Associates, LLC, Relamatrix Group,Inc. Previous NAMM California, Hemet Valley Medical Center, Phoenix Health Systems Development Education Hallock High School Recommendations 1 person has recommended David Experience President Gustafson + Associates, LLC January 2007 – Present (9 years 2 months) Hospital and Healthcare related Interim Leadership, Project Management, Program Development and Company Incubation. Senior Corporate Ambassador Relamatrix Group,Inc. 2007 – Present (9 years) Executive Director NAMM California July 2012 – October 2014 (2 years 4 months) Executive Director of PrimeCare of Temecula and Sun City. Two IPAs with 42,000 managed care members. Hospital CEO Hemet Valley Medical Center 2005 – 2006 (1 year)Greater Los Angeles Area CEO of this general acute medical surgical hospital owned by a hospital district. Stimulated patient flow activity through actions resulting in improved patient throughput, increased bed availability and shortened ER wait times during a time of increasing patient volumes; reduced Left Without Being Seen rate in ER from over 14% to 3% resulting in the capture of additional revenues for this department and admissions to the hospital; implemented a variety of initiatives that improved all patient satisfaction indicators; elevated medical quality; reduced overall productive FTE’s by 3% while concurrently selectively increasing staff to accommodate regulatory compliance requirements; presided over remodel and business plan development for upgraded Radiation Oncology Department; implemented PACS system in Radiology Department as well as several other hospital wide IT initiatives Principal Phoenix Health Systems Development August 2003 – November 2005 (2 years 4 months)Greater Los Angeles Area Engaged in a variety of healthcare projects, mostly focused on business development activity. Provided leadership to a hospital in crisis averting closure by Dept. of Health Services for serious patient safety and governance deficiencies while simultaneously increasing census by over 80%. CEO for several different hospitals in this system Alta Healthcare System March 2002 – August 2003 (1 year 6 months)Greater Los Angeles Area Focused case management efforts reducing Medi-Cal denials by 20%; brought about operating efficiencies by reducing staff and virtually eliminating overtime; put one hospital on fast track to JCAHO survey readiness and received minimal Type I recommendations President Pacific Integrated Healthcare, Inc August 1993 – March 2002 (8 years 8 months)Greater Los Angeles Area Management support to physician offices, facilitating growth of practice to accommodate sale; During this time founded and concurrently operated California Osteoporosis Institute, a company that pioneered low cost, retail oriented bone densitometry in multiple sites throughout Southern California. CEO Panorama Community Hospital May 1990 – July 1993 (3 years 3 months)Greater Los Angeles Area Led hospital during time of transition from proprietary corporate ownership to local, not-for-profit control. Guided development of hospital affiliated IPA; in collaboration with an LA based IPA developed a two county primary care hospital and physician network for managed care contracting purposes. Consultant Blue Cross of California September 1989 – April 1990 (8 months)Greater Los Angeles Area Major project in the development of a revolutionary managed care product for psychiatric and chemical dependency treatment. CEO Woodview Calabasas Hospital February 1988 – August 1989 (1 year 7 months)Greater Los Angeles Area CEO of this HCA managed, psychiatric hospital. Developed new service lines and restructured management team creating new, positive organizational culture. CEO Valley Hospital Medical Center February 1986 – January 1988 (2 years)Greater Los Angeles Area CEO of this HealthWest owned institution. Initiated development and construction of on-campus MOB and 600 car parking structure; initiated micro-surgery program; established case management system focusing on appropriate utilization resulting in a 10% reduction in length of stay; introduced hospital to risk contracting; guided development of IPA. CEO Memorial Medical Center November 1979 – January 1986 (6 years 3 months)Sioux Falls, South Dakota Area CEO of this Health Central, Inc. managed community hospital. Provided leadership for and orchestrated the successful merger of the community's two hospitals; developed management team at all levels resulting in a turnaround of the organization's culture, averting a unionization attempt; initiated multiple new services. Volunteer Experience & Causes Causes David cares about: Animal Welfare Arts and Culture Children Health Human Rights Science and Technology
MultiCorp International, Inc. to Develop 4 Arm Study for Emergency Room Clinical Trials With Patented Migraine Medicine SUN VALLEY, CA, Jan 21, 2016 (Marketwired via COMTEX) -- MultiCorp International, Inc. (otc pink:MCIC) has received a report from the U.S. Food and Drug Administration that gives the company specific guidelines in creating a 4 arm study to administer the patented migraine medicine in an emergency room setting.
The company released the following statement: "The company has received a detailed response to the Pre-IND submission sent to the U.S. Food and Drug Administration for the further development of the patented migraine medicine the company has ownership in. The FDA has responded in supplying the company with a clear roadmap to develop a 4 arm study wherein the medicine will be dispensed in an emergency room setting for patients that enter the ER for migraine relief. This study will give the company feedback on the efficacy of the drug as compared to other medications currently being dispensed to relieve migraines. This study significantly will speed up the process to bring the product to market." The company also stated it is suspending all other areas of business to focus 100% on the further development of the medicine. As the migraine industry in the U.S. is currently in excess of $800 Million per year, the company feels that this medicine could capture a 10-15% market share which would place a value of the medicine at $80-$120 Million.
Compass Point Research to Collaborate With NDA Partners to Develop Migraine Combination Drug
NASHVILLE, TN, Apr 07, 2015 (Marketwired via COMTEX) -- Lori Nesbitt, PharmD, Chief Executive Officer of Compass Point Research, announced today that the company has entered into an agreement with NDA Partners LLC, a highly regarded medical product development and regulatory strategy consultancy, to collaborate in the development of a new combination drug for the treatment of migraine headaches. Compass Point has been retained by the drug sponsor, MultiCorp International, Inc., a publicly traded company located in Sun Valley, CA, to manage the product development program, and NDA Partners will provide the drug development and regulatory expertise needed to prepare a development plan for a 505(b)(2) NDA submission to the US Food & Drug Administration (FDA) and to manage a preIND meeting with the FDA review division.
The product is a combination of two currently FDA approved drugs, diphenhydramine (Benadryl(R)) and trimethobenzamide (Tebamide(R), Tigan(R)), both of which can be delivered in an oral dosage form. Diphenhydramine is used clinically in combination with other dopamine antagonists such as prochloperazine and metoclopramide as first line therapy to treat migraine headaches. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting. In an emergency department-based clinical study conducted in 2005, the drug combination, delivered as a single injection intramuscularly, demonstrated pain relief, tolerability, and efficacy at 24 hours compared to subcutaneous sumatriptan.
NDA Partners has assembled a highly experienced product development team with comprehensive expertise that includes regulatory strategy, nonclinical development, toxicology, CMC, clinical pharmacology, and experience in demonstration of clinical effectiveness of new migraine treatments. The team will be led by Charles Grudzinskas, PhD, a Partner in the firm who has led efforts to develop and register dozens of new medical products, and includes David Feigal, MD, former Director, FDA Center for Devices & Radiological Health (CDRH); Jeanine Kuczik, a Partner in NDA Partners with significant experience in the development of migraine treatments; and Anthony DiSanto, PhD, former Vice President of Worldwide Drug Delivery Research & Development for the Upjohn Company.
"We are very pleased to be able to combine our extensive drug development and operational experience with world class development and regulatory experts from NDA Partners," said Dr. Nesbitt. "Together, we will deliver an outstanding solution for our client."
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include two former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of approximately 60 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.
MultiCorp International, Inc. (Sun Valley, CA) is a diversified company that operates in various business sectors including property development, constructions, medical, and hospitality as well as commodities such as oil and gas, and entertainment. The vision of management for the company is to diversify into many fields wherein management's expertise, along with its strategic partner's experience, will enable it to participate in high growth markets and increase profitability.
"This is an important program for us, and we believe we have a potential break-through product under development that can provide longer-lasting relief for those suffering from migraine headaches," said Ben Friedman, Rph and President of MultiCorp International, Inc. "Compass Point has assembled an outstanding team to help us develop this product, and we look forward to working with them to fill this important medical need."
About Compass Point Research
Compass Point Research is a full-service clinical and translational research management and consulting firm. The company's focus is on facilitating all aspects of clinical trials operations for community-based healthcare providers, including drug, device, nutritional supplement and consumer product development from discovery through clinical studies, and post-approval support. In addition, Compass Point develops and coordinates multi-center outcomes and registry trials for industry sponsors, healthcare providers and payers, delivering scientifically rigorous research outcomes in an affordable environment. The company has been able to assist providers with not only eliminating a subsidy for research, but actually realizing a net profit for the department or cost center while adhering to all governing regulations and internal standard operating procedures.
Contact Lori A. Nesbitt, PharmD, MBA Chief Executive Officer Office: 615-522-5424 Mobile: 615-418-8987 Fax: 615-522-5401 Email: [email protected]
SOURCE: Compass Point Research
(C) 2015 Marketwire L.P. All rights reserved.
Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication
Company Seeking Clinical Trial Partner to Begin Testing in First Quarter of 2014
SUN VALLEY, CA--(Marketwired - Dec 17, 2013) - MultiCorp International, Inc, (OTC Pink: MCIC) has acquired a 70% stake in a patented migraine medication. The company released the following statement:
"MultiCorp International, Inc has acquired a 70% ownership in a patented migraine medicine that has shown to aid in the symptoms of migraine headaches. According to www.migraine.com in the U.S. alone more than 37 million people suffer from migraines and globally over 330 million people have migraines on a constant basis. The medication was developed by a physician that MultiCorp will work closely with in order to gain FDA approval for the medication. The company plans to begin clinical trials in the first quarter of 2014 and hope to have the medication to market as soon as possible. The information on the patent can be found at http://www.faqs.org/patents/app/20090018205. Under the terms of the agreement, MultiCorp will have full authority to oversee the clinical trials of the product, marketing and selling of the medication, as well the overall business of getting the product to market as quickly as possible and retaining a 70% interest in the product. With the average cost of $145 per month in medication for migraine sufferers, the market for this product is exponential here in the U.S. and globally."
For companies wishing to assist MultiCorp in clinical trials, please email us at [email protected]